Table 1 Laboratory parameters before institution of atorvastatin treatment (visit 1) and after 3 months (visit 2)
HS (n = 17) | Pts (n = 30) | |||||
|---|---|---|---|---|---|---|
P* vs Pts | P** | |||||
Visit 1 | Visit 2 | Visit 1 | Visit 2 | Visit 2 vs 1 | ||
Tot-c (mg/dL) | 198.0 (188.5–221.5) | <0.0001 | 0.036 | 269.0 (226.0–318.0) | 166.0 (141.5–204.5) | <0.0001 |
LDL-c (mg/dL) | 115.0 (107.0–147.5) | 0.003 | n.s. | 168.0 (119.3–263.5) | 135.0 (94.0–196.5) | 0.0013 |
HDL-c (mg/dL) | 53.0 (44.0–67.5) | n.s. | n.s. | 49.5 (42.8–56.3) | 47.0 (39.5–54.5) | n.s. |
TG (mg/dL) | 132.0 (102.5–163.5) | 0.002 | 0.0004 | 181.5 (137.7–220.6) | 87.0 (61.2–111.9) | <0.0001 |
ApoA (mg/dL) | 144.0 (121.5–161.0) | n.s. | n.s. | 126.0 (114.3–139.5) | 130.0 (112.0–143.5) | n.s. |
ApoB (mg/dL) | 98.0 (85.0–108.5) | <0.0001 | 0.038 | 139.0 (120.0–155.0) | 80.0 (64.0–.98.0) | <0.0001 |
hs-CRP (mg/L) | 1.50 (0.60–2.70) | n.s. | n.s. | 0.90 (0.45–2.20) | 1.1 (0.7–2.4) | n.s. |
Glucose (mg/dL) | 96 (89–97) | n.s. | n.s. | 93.5 (89.75–102) | 96 (89.75–100) | n.s. |